vs
Side-by-side financial comparison of STEM, INC. (STEM) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $34.1M, roughly 1.4× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs -15.6%). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 36.1%).
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
STEM vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.1M | $34.1M |
| Net Profit | $-16.0M | — |
| Gross Margin | 48.9% | — |
| Operating Margin | -17.7% | 27.3% |
| Net Margin | -33.9% | — |
| Revenue YoY | -15.6% | 183.4% |
| Net Profit YoY | 68.8% | — |
| EPS (diluted) | $-4.40 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.1M | $34.1M | ||
| Q3 25 | $38.2M | $26.1M | ||
| Q2 25 | $38.4M | $25.9M | ||
| Q1 25 | $32.5M | $20.4M | ||
| Q4 24 | $55.8M | $12.0M | ||
| Q3 24 | $29.3M | $3.7M | ||
| Q2 24 | $34.0M | $4.4M | ||
| Q1 24 | $25.5M | $3.4M |
| Q4 25 | $-16.0M | — | ||
| Q3 25 | $-23.8M | $-544.0K | ||
| Q2 25 | $202.5M | $74.7M | ||
| Q1 25 | $-25.0M | $-3.1M | ||
| Q4 24 | $-51.1M | — | ||
| Q3 24 | $-148.3M | $-33.2M | ||
| Q2 24 | $-582.3M | $-19.9M | ||
| Q1 24 | $-72.3M | $-16.6M |
| Q4 25 | 48.9% | — | ||
| Q3 25 | 35.5% | — | ||
| Q2 25 | 33.4% | — | ||
| Q1 25 | 32.4% | — | ||
| Q4 24 | -4.4% | — | ||
| Q3 24 | 21.2% | — | ||
| Q2 24 | 27.6% | — | ||
| Q1 24 | -95.0% | — |
| Q4 25 | -17.7% | 27.3% | ||
| Q3 25 | -33.6% | 15.9% | ||
| Q2 25 | -34.8% | -274.5% | ||
| Q1 25 | -65.0% | -26.3% | ||
| Q4 24 | -84.4% | -128.0% | ||
| Q3 24 | -493.2% | -739.0% | ||
| Q2 24 | -1705.5% | -534.8% | ||
| Q1 24 | -267.0% | -598.1% |
| Q4 25 | -33.9% | — | ||
| Q3 25 | -62.2% | -2.1% | ||
| Q2 25 | 527.8% | 288.7% | ||
| Q1 25 | -76.9% | -15.2% | ||
| Q4 24 | -91.6% | — | ||
| Q3 24 | -506.3% | -899.2% | ||
| Q2 24 | -1712.6% | -447.9% | ||
| Q1 24 | -283.9% | -485.3% |
| Q4 25 | $-4.40 | — | ||
| Q3 25 | $-2.84 | $-0.01 | ||
| Q2 25 | $-1.79 | $1.21 | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-15.29 | — | ||
| Q3 24 | $-18.24 | $-0.69 | ||
| Q2 24 | $-71.81 | $-0.48 | ||
| Q1 24 | $-0.46 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $48.9M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $-249.4M | $154.7M |
| Total Assets | $308.9M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.9M | $62.4M | ||
| Q3 25 | $43.1M | $54.4M | ||
| Q2 25 | $40.8M | $47.7M | ||
| Q1 25 | $58.6M | $37.3M | ||
| Q4 24 | $56.3M | $33.8M | ||
| Q3 24 | $75.4M | $54.0M | ||
| Q2 24 | $89.6M | $39.3M | ||
| Q1 24 | $112.8M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-249.4M | $154.7M | ||
| Q3 25 | $-235.7M | $133.2M | ||
| Q2 25 | $-214.1M | $117.2M | ||
| Q1 25 | $-417.5M | $41.0M | ||
| Q4 24 | $-398.4M | $39.7M | ||
| Q3 24 | $-344.1M | $69.8M | ||
| Q2 24 | $-203.2M | $32.5M | ||
| Q1 24 | $371.6M | $48.8M |
| Q4 25 | $308.9M | $284.7M | ||
| Q3 25 | $362.6M | $270.1M | ||
| Q2 25 | $379.2M | $256.3M | ||
| Q1 25 | $405.1M | $172.7M | ||
| Q4 24 | $437.4M | $178.1M | ||
| Q3 24 | $537.8M | $191.6M | ||
| Q2 24 | $691.5M | $144.4M | ||
| Q1 24 | $1.3B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $5.5M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 16.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $5.5M | ||
| Q3 25 | $11.4M | $4.7M | ||
| Q2 25 | $-21.3M | $-3.6M | ||
| Q1 25 | $8.5M | $-8.2M | ||
| Q4 24 | $-14.7M | $-16.3M | ||
| Q3 24 | $-9.4M | $-18.1M | ||
| Q2 24 | $-11.9M | $-19.1M | ||
| Q1 24 | $-621.0K | $-16.2M |
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 16.1% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | -14.7% | ||
| Q1 25 | — | -40.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.11× | -0.05× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STEM
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
